Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2009 1
2010 1
2011 1
2012 1
2013 3
2014 1
2015 2
2016 1
2018 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, Coma S, Kumada Y, Yamany MS, Sentandreu E, Fromm G, Tiziani S, Schreiber TH, Manfredi M, Ehrlich LIR, Stone E, Georgiou G. Triplett TA, et al. Among authors: coma s. Nat Biotechnol. 2018 Sep;36(8):758-764. doi: 10.1038/nbt.4180. Epub 2018 Jul 16. Nat Biotechnol. 2018. PMID: 30010674 Free PMC article.
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma.
Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Gomes F, Arang N, Tiago M, Coma S, Lubrano S, Wu X, Ford K, Day CP, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, Gutkind JS. Paradis JS, et al. Among authors: coma s. Clin Cancer Res. 2021 Jun 1;27(11):3190-3200. doi: 10.1158/1078-0432.CCR-20-3363. Epub 2021 Feb 10. Clin Cancer Res. 2021. PMID: 33568347
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page